Avails Medical Announces FDA Clearance of its eQUANT™ System to Accelerate Workflow for Antibiotic Susceptibility Testing
MENLO PARK, February 20, 2024 (Newswire.com) – Avails Medical, Inc., a leader in the development of rapid, automated and fully electrical antibiotic susceptibility testing (AST) technologies, announced it has received…
Read More
Avails Medical’s eQUANT™ system submitted to FDA for 510(k) clearance
MENLO PARK, Calif., June 12, 2023 /PRNewswire/ -- Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (AST) solutions announced today the submission of its eQUANT™…
Read More
Avails Medical awarded additional $1.7M in CARB-X funding for the development of its rapid antibiotic susceptibility testing device to identify the most effective antibiotic therapy
MENLO PARK, Calif., Sept. 1, 2022 /PRNewswire/ -- Avails Medical, a pioneer in rapid, automated, and fully electrical antibiotic susceptibility testing (eAST™) announced today the transition to the next phase…
Read More
Avails Medical announces the commencement of U.S. Pivotal Clinical Trials for eQUANT™
MENLO PARK, Calif. , Aug. 15, 2022 /PRNewswire/ -- Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (eAST™) announced today the commencement of U.S. pivotal clinical…
Read More
EVENTS
ECCMID 2023
April 15-18
Copenhagen, Denmark
Booth B5-04
ASM Microbe 23
June 15-19
Houston, Texas